• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Statins: are they appropriate for all patients?他汀类药物：它们适用于所有患者吗？
Lancet Glob Health. 2022 Mar;10(3):e305-e306. doi: 10.1016/S2214-109X(21)00572-6.
2
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis.羟甲基戊二酰辅酶 A 还原酶抑制剂（他汀类药物）治疗成人脓毒症的系统评价和荟萃分析。
Clin Microbiol Infect. 2019 Mar;25(3):280-289. doi: 10.1016/j.cmi.2018.11.003. Epub 2018 Nov 23.
3
Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.血管紧张素转换酶（ACE）和羟甲基戊二酰辅酶 A（HMG-CoA）还原酶抑制剂处于内皮细胞药理学的前沿。
Pharmacol Rep. 2005;57 Suppl:86-96.
4
The HMG-CoA reductase pathway, statins and angioprevention.HMG-CoA还原酶途径、他汀类药物与血管保护作用
Semin Ophthalmol. 2006 Jan-Mar;21(1):29-35. doi: 10.1080/08820530500509382.
5
Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.羟甲基戊二酰辅酶A还原酶抑制剂在骨质疏松症管理中的应用
Ann Pharmacother. 2002 Feb;36(2):326-30. doi: 10.1345/aph.1A071.
6
[Anti-inflammatory effect of HMG-CoA reductase inhibitors].[HMG-CoA还原酶抑制剂的抗炎作用]
Nihon Rinsho. 2004 Jan;62(1):172-9.
7
Call for a moratorium on routine liver function testing in patients treated with HMG-CoA reductase inhibitors (statins).
Clin Ther. 2011 Nov;33(11):1696-7. doi: 10.1016/j.clinthera.2011.09.018.
8
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂在中枢神经系统疾病治疗中的应用
Arch Neurol. 2010 Sep;67(9):1062-7. doi: 10.1001/archneurol.2010.199.
9
Statins as potential therapeutic agents in multiple sclerosis.他汀类药物作为多发性硬化症的潜在治疗药物。
Curr Neurol Neurosci Rep. 2004 May;4(3):237-44. doi: 10.1007/s11910-004-0044-2.
10
HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention.HMG-CoA还原酶抑制剂（他汀类药物）：一种有前景的中风预防方法。
Neurology. 2000 Oct 10;55(7):1066-7. doi: 10.1212/wnl.55.7.1066.

引用本文的文献

1
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects.以PCSK9和其他生物分子为靶点的口服和非口服降胆固醇药物：现状与未来前景
Biomolecules. 2025 Mar 22;15(4):468. doi: 10.3390/biom15040468.
2
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.血脂异常管理中获取新兴疗法的障碍及潜在解决方案
J Clin Med. 2024 Jul 16;13(14):4160. doi: 10.3390/jcm13144160.
3
The burden of metabolic risk factors in North Africa and the Middle East, 1990-2019: findings from the Global Burden of Disease Study.1990 - 2019年北非和中东地区代谢风险因素负担：全球疾病负担研究的结果
EClinicalMedicine. 2023 Jun 2;60:102022. doi: 10.1016/j.eclinm.2023.102022. eCollection 2023 Jun.

本文引用的文献

1
Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.在 41 个低收入和中等收入国家中使用他汀类药物预防心血管疾病：基于国家代表性、个体水平数据的横断面研究。
Lancet Glob Health. 2022 Mar;10(3):e369-e379. doi: 10.1016/S2214-109X(21)00551-9.
2
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).家族性高胆固醇血症的全球视角：来自 EAS 家族性高胆固醇血症研究协作组（FHSC）的横断面研究。
Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3. Epub 2021 Sep 7.
3
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.欧盟范围内二级和初级保健中使用调脂治疗的横断面观察性研究：DA VINCI 研究。
Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289. doi: 10.1093/eurjpc/zwaa047.
4
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担：2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
5
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.家族性高胆固醇血症在普通人群和动脉粥样硬化性心血管疾病患者中的患病率：系统评价和荟萃分析。
Circulation. 2020 Jun 2;141(22):1742-1759. doi: 10.1161/CIRCULATIONAHA.119.044795. Epub 2020 May 29.
6
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病。1. 来自遗传、流行病学和临床研究的证据。欧洲动脉粥样硬化学会共识小组的共识声明。
Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
7
Interpretation of the evidence for the efficacy and safety of statin therapy.他汀类药物治疗疗效和安全性证据解读。
Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8.
8
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.他汀类药物降低 LDL 胆固醇对低血管疾病风险人群的影响：27 项随机试验个体数据的荟萃分析。
Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
9
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.降低胆固醇治疗的疗效与安全性：对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.

Statins: are they appropriate for all patients?

作者信息

Raal Frederick J, Mohamed Farzahna

机构信息

Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, 2193 Johannesburg, South Africa.

Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, 2193 Johannesburg, South Africa.

出版信息

Lancet Glob Health. 2022 Mar;10(3):e305-e306. doi: 10.1016/S2214-109X(21)00572-6.

DOI:10.1016/S2214-109X(21)00572-6
PMID:35180403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8846614/
Abstract
摘要